The full meeting agenda and abstracts for the upcoming Genitourinary Cancers Symposium (co-sponsored by ASCO and others) are now available on line. The prostate cancer session will start tomorrow morning in San Francisco; unfortunately we have not been able to send a reporter to this meeting this year.
You can scan the agenda and read abstracts of relevant prostate cancer studies if you click here.
The “New” Prostate Cancer InfoLink will be looking through these abstracts and monitoring media reports with care over the next few days to see if we can spot any real “pearls” of wisdom. We do already know that full data from the initial Phase III trial of MDV3100 (in men with metastatic castration-resistant prostate cancer who have been treated with at least one cycle of chemotherapy) are to be presented at this meeting for the first time.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment
Search for new and
ongoing trials on the
CTAG PCa web site
There has been amazing progress in the last few years in mCRPC — and it seems like the trend might continue. Take a look at OGX427′s pre-chemotherapy trial data.
The size of the trial is small but OGX427′s PSA and CTC data seem interesting. The primary endpoint (number of patients with a PSA decline at 12 weeks) is better than MDV3100′s pre-chemotherapy trial, even though the patients were sicker.